The role of the ETS factor erg in zebrafish vasculogenesis.

Mechanisms of Development
Felix EllettGraham J Lieschke

Abstract

Erg, a member of the ETS family of transcription factors, has been implicated by previous studies in endothelial and haematopoietic development. Deregulation of the human ERG locus is associated with acute myeloid leukaemia, prostate cancer and Ewing's sarcoma. To better understand the role of Erg during early development, we utilised the zebrafish as a model amenable to descriptive and functional studies in vivo. Zebrafish have a single erg gene that is expressed in mesoderm and its vascular derivatives during angioblast migration, vasculogenesis and early angiogenesis. Mutant and morphant expression analyses placed erg in a genetic pathway downstream of cloche, tal1/scl and etsrp during early angioblast migration. Furthermore, a combination of gain-of-function and loss-of-function studies suggested a redundant yet specific role for erg in both angioblast specification/proliferation and early angiogenesis, and a synergistic interaction with the critical ETS factor etsrp.

References

Sep 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·E S ReddyT S Papas
Jan 14, 2000·Developmental Dynamics : an Official Publication of the American Association of Anatomists·M BaltzingerP Remy
Apr 18, 2002·Proceedings of the National Academy of Sciences of the United States of America·Susan E LyonsP Paul Liu
Aug 9, 2002·Developmental Biology·Nathan D Lawson, Brant M Weinstein
Aug 27, 2002·Current Biology : CB·Hinrich HabeckUNKNOWN Tübingen 2000 screen consortium
Feb 1, 2003·Gene·Tsuneyuki Oikawa, Toshiyuki Yamada
Sep 4, 2003·The Journal of Cell Biology·Michelle L McWhorterChristine E Beattie
Dec 8, 2004·Developmental Biology·Benjamin M HoganGraham J Lieschke
Dec 25, 2004·Developmental Biology·Kimberly A DooleyLeonard I Zon
Dec 29, 2004·Developmental Cell·Jennifer RhodesJohn P Kanki
Dec 29, 2004·Developmental Cell·Jenna L GallowayLeonard I Zon
Apr 14, 2005·Blood·Gerhard J WeberLeonard I Zon
Oct 29, 2005·Science·Scott A TomlinsArul M Chinnaiyan
Dec 13, 2005·PLoS Biology·Saulius Sumanas, Shuo Lin
Nov 28, 2006·Developmental Biology·Van N PhamBrant M Weinstein
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciUNKNOWN Cancer and Leukemia Group B Study
Jun 3, 2008·PLoS Genetics·Jeroen BussmannUNKNOWN Zebrafish Nomenclature Committee

❮ Previous
Next ❯

Citations

Sep 29, 2012·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Maisa YoshimotoAndrew J Evans
Sep 9, 2010·Bioinformatics·Geoff MacintyreAdam Kowalczyk
Mar 13, 2012·Current Opinion in Hematology·Kelly Lammerts van Bueren, Brian L Black
Oct 21, 2011·Genes & Development·Peter C HollenhorstBarbara J Graves
Sep 29, 2011·Seminars in Cell & Developmental Biology·Stryder M MeadowsPaul A Krieg
Apr 30, 2016·Angiogenesis·Michael P Craig, Saulius Sumanas
Apr 7, 2017·Nature Communications·Maria-Cristina KeightleyGraham J Lieschke
Feb 15, 2012·Nature Reviews. Urology·Philip RosenAlbert Dobi
May 28, 2021·Frontiers in Cell and Developmental Biology·Luok Wen YongJr-Kai Yu

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.